1. Home
  2. FOR vs ABCL Comparison

FOR vs ABCL Comparison

Compare FOR & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Forestar Group Inc

FOR

Forestar Group Inc

HOLD

Current Price

$27.79

Market Cap

1.4B

Sector

Finance

ML Signal

HOLD

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$6.15

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FOR
ABCL
Founded
2005
2012
Country
United States
Canada
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.3B
IPO Year
2007
2020

Fundamental Metrics

Financial Performance
Metric
FOR
ABCL
Price
$27.79
$6.15
Analyst Decision
Buy
Strong Buy
Analyst Count
3
5
Target Price
$32.67
$8.40
AVG Volume (30 Days)
121.2K
8.0M
Earning Date
04-21-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
10.91
EPS
0.93
N/A
Revenue
$1,662,400,000.00
$75,128,000.00
Revenue This Year
$0.34
N/A
Revenue Next Year
$7.73
$21.85
P/E Ratio
$29.49
N/A
Revenue Growth
10.14
160.56
52 Week Low
$18.73
$2.02
52 Week High
$30.74
$6.52

Technical Indicators

Market Signals
Indicator
FOR
ABCL
Relative Strength Index (RSI) 58.69 74.81
Support Level $24.22 $3.32
Resistance Level $29.05 $6.52
Average True Range (ATR) 0.84 0.46
MACD 0.12 0.12
Stochastic Oscillator 85.00 97.17

Price Performance

Historical Comparison
FOR
ABCL

About FOR Forestar Group Inc

Forestar Group Inc is a residential lot development company engaged in land acquisition and development for the sale of finished single-family residential lots to local, regional, and national homebuilders. The company operates through a single real estate segment, which acquires land, installs infrastructure for residential communities, and generates all revenue from lot sales. Its communities mainly support entry-level, first-time move-up, and active-adult homes, with certain communities also marketed to build-to-rent operators. The company generally invests in entitled, short-duration projects that can be developed in phases to align lot production with market demand and support efficient capital deployment.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Share on Social Networks: